Clinical Trial Update: A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 study comparing ustekinumab versus guselkumab in pediatric participants with active juvenile psoriatic arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Juvenile
• Juvenile Psoriatic Arthritis

Drugs mentioned

• Guselkumab (guselkumab)
• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Juvenile | Phase 3 | Status: COMPLETED